. With the advent of sequencing and cloning immunodominant antigens of T. cruzi came the development of tests using recombinant protein mixtures of the parasite and/or synthetic peptides which resulted in an increase in the sensitivity and specificity. Moreover, it was only with Resolution 343 of December 13, 2002, that highly sensitive blood donor screening for Chagas disease using an enzyme immunoassay (EIA) test was established as compulsory.
At the same time, the blood transfusion services gradually implemented a set of quality control measures and introduced computer systems, which together, gradually reduced the number of erroneous and inconclusive results.
In this study by Pereira et al. (4) , the prevalence found in the group of inconclusive samples was 13.3%; Remesar et al. (7) reported a prevalence of 18% in Chaco province, Argentina, where the prevalence of the disease is high (24.5%), Otani et al. (8) found 17% in samples collected from ten Latin America countries and Sabino et al. reported a prevalence of 20% for Brazil in the International Retrovirus Epidemiology Donor Study-II (REDS-II) (9) . An understanding of the meaning of results with low reactivity in screening tests to detect anti-T. cruzi antibodies however has not been reached. Sabino et al. (in press ) report that the drop in the S/ CO index in ten patients with negative results for Chagas disease using a polymerase chain reaction technique may be an indication of seroreversion as a result of a spontaneous cure of the disease.
The current work shows that the interpretation of the results of serology screening for anti-T. cruzi in association with the epidemiological data is strategically important for blood safety and for the diagnosis of Chagas disease (4) .
Rev Bras Hematol Hemoter. 2012;34(4):254-64 xxx
